Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas

Human Pathology

Volumn 42, Issue 11, 2011, Pages 1702-1709

  Guedj, Nathalie ^a   Bretagnol, Frédéric ^a   Rautou, Pierre Emmanuel ^a   Deschamps, Lydia ^a   Cazals Hatem, Dominique ^a   Bedossa, Pierre ^a   Panis, Yves ^a   Couvelard, Anne ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Chemoradiotherapy; Pathologic response; Rectal adenocarcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GLUCOSE TRANSPORTER 1;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; FEMALE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RECTUM BIOPSY; RECTUM CARCINOMA; RECTUM SURGERY; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANOXIA; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS;

EID: 80054708625     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.01.015     Document Type: Article

References (35)

1. Medich D., McGinty J., and Parda D. Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications Dis Colon Rectum 44 2001 1123 1128 (Pubitemid 32758267)
2. Bosset J.F., Collette L., and Calais G. Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123 (Pubitemid 44394918)
3. Balch G.C., De Meo A., and Guillem J.G. Modern management of rectal cancer: a 2006 update World J Gastroenterol 12 2006 3186 3195 (Pubitemid 43881342)
4. Glynne-Jones R., and Harrison M. Locally advanced rectal cancer: what is the evidence for induction chemoradiation? Oncologist 12 2007 1309 1318 (Pubitemid 350237606)
5. Tulchinsky H., Shmueli E., Figer A., Klausner J.M., and Rabau M. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer Ann Surg Oncol 15 2008 2661 2667
6. Alves A., Panis Y., Mathieu P., Mantion G., Kwiatkowski F., and Slim K. Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study Arch Surg 140 2005 278 283 [discussion 284] (Pubitemid 41001821)
7. Lezoche E., Guerrieri M., Paganini A.M., Baldarelli M., De Sanctis A., and Lezoche G. Long-term results in patients with T2-3 N0 distal rectal cancer undergoing radiotherapy before transanal endoscopic microsurgery Br J Surg 92 2005 1546 1552 (Pubitemid 41785295)
8. Denecke T., Rau B., and Hoffmann K.T. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol 15 2005 1658 1666 (Pubitemid 41102362)
9. Huh J.W., Park Y.A., Jung E.J., Lee K.Y., and Sohn S.K. Accuracy of endorectal ultrasonography and computed tomography for restaging rectal cancer after preoperative chemoradiation J Am Coll Surg 207 2008 7 12
10. Tytherleigh M.G., Ng V.V., Pittathankal A.A., Wilson M.J., and Farouk R. Preoperative staging of rectal cancer by magnetic resonance imaging remains an imprecise tool ANZ J Surg 78 2008 194 198 (Pubitemid 351207399)
11. Hiotis S.P., Weber S.M., and Cohen A.M. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients J Am Coll Surg 194 2002 131 135 [discussion 135-6]
12. Smith F.M., Waldron D., and Winter D.C. Rectum-conserving surgery in the era of chemoradiotherapy Br J Surg 97 2010 1752 1764
13. Chong T.W., Horwitz L.D., Moore J.W., Sowter H.M., and Harris A.L.A. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines Cancer Res 62 2002 6924 6927 (Pubitemid 35424082)
14. Semenza G.L. Targeting HIF-1 for cancer therapy Nat Rev Cancer 3 2003 721 732 (Pubitemid 37328811)
15. Quirke P., Durdey P., Dixon M.F., and Williams N.S. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision Lancet 2 1986 996 999 (Pubitemid 16005611)
16. Wheeler J.M., Warren B.F., and Mortensen N.J. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system Dis Colon Rectum 45 2002 1051 1056
17. Habr-Gama A., Perez R.O., and Nadalin W. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results Ann Surg 240 2004 711 717 [discussion 717-8]
18. Ruo L., Guillem J.G., Minsky B.D., Quan S.H., Paty P.B., and Cohen A.M. Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers Int J Colorectal Dis 17 2002 54 58 (Pubitemid 41398993)
19. Hughes R., Glynne-Jones R., and Grainger J. Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision? Int J Colorectal Dis 21 2006 11 17 (Pubitemid 41829760)
20. Jakob C., Liersch T., Meyer W., Becker H., Baretton G.B., and Aust D.E. Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy World J Gastroenterol 14 2008 1060 1066 (Pubitemid 351325006)
21. Read T.E., Andujar J.E., and Caushaj P.F. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status Dis Colon Rectum 47 2004 825 831 (Pubitemid 38702600)
22. Zmora O., Dasilva G.M., and Gurland B. Does rectal wall tumor eradication with preoperative chemoradiation permit a change in the operative strategy? Dis Colon Rectum 47 2004 1607 1612 (Pubitemid 39331970)
23. Ratto C., Ricci R., and Valentini V. Neoplastic mesorectal microfoci (MMF) following neoadjuvant chemoradiotherapy: clinical and prognostic implications Ann Surg Oncol 14 2007 853 861 (Pubitemid 46175336)
24. Ratto C., Ricci R., Rossi C., Morelli U., Vecchio F.M., and Doglietto G.B. Mesorectal microfoci adversely affect the prognosis of patients with rectal cancer Dis Colon Rectum 45 2002 733 742 [discussion 742-33] (Pubitemid 34602485)
25. Benzoni E., Terrosu G., and Intersimone D. Instrumental clinical restaging, pathological evaluation, and tumor regression grading: how to assess the response to neoadjuvant chemoradiotherapy for rectal cancer Int J Colorectal Dis 22 2007 7 13 (Pubitemid 44742333)
26. Theodoropoulos G., Wise W.E., and Padmanabhan A. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival Dis Colon Rectum 45 2002 895 903 (Pubitemid 34761469)
27. Kim N.K., Baik S.H., and Seong J.S. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: impact of postirradiated pathologic downstaging on local recurrence and survival Ann Surg 244 2006 1024 1030 (Pubitemid 44808646)
28. Bouzourene H., Bosman F.T., Seelentag W., Matter M., and Coucke P. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy Cancer 94 2002 1121 1130 (Pubitemid 34150868)
29. Wykoff C.C., Beasley N.J., and Watson P.H. Hypoxia-inducible expression of tumor-associated carbonic anhydrases Cancer Res 60 2000 7075 7083 (Pubitemid 32059187)
30. Rasheed S., Harris A.L., and Tekkis P.P. Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis Br J Cancer 100 2009 1666 1673
31. Rasheed S., Harris A.L., and Tekkis P.P. Assessment of microvessel density and carbonic anhydrase-9 (CA-9) expression in rectal cancer Pathol Res Pract 205 2009 1 9
32. Cooper R., Sarioglu S., and Sokmen S. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 89 2003 870 876 (Pubitemid 37175810)
33. Theodoropoulos G.E., Lazaris A.C., and Theodoropoulos V.E. Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer Int J Colorectal Dis 21 2006 248 257 (Pubitemid 43280332)
34. Korkeila E., Talvinen K., and Jaakkola P.M. Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer Br J Cancer 100 2009 874 880
35. 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study Dis Colon Rectum 51 2008 1641 1648